TitleCancer Therapeutic with Increased Efficacy and Reduced Side Effects
OwnerUniversity of Florida
Uses Small Drug-Like Molecules to Prevent Cancer Cell Proliferation This breakthrough approach to treating cancer is efficacious and has limited side effects. Cancer is a leading cause of death in the United States, accounting for one in four deaths annually, according to the American Cancer Society. An estimated 595,600 Americans will die of cancer-related causes in 2016, and predictions for the future continue to rise. Existing treatments often suffer from a lack of efficacy or lead to debilitating side effects for the patient. Researchers at the University of Florida have developed a distinct therapy to specifically target cancerous cell proliferation and halt the growth of tumors and the spread of cancer. This breakthrough treatment also has minimal side effects, making it a desirable treatment for both the patient and health practitioner. Application A therapeutic cancer treatment that inhibits the proliferation of cancer Advantages Capable of preventing and treating cancer and other cell proliferation diseases, offering a therapy that is effective at a lower concentrations Decreases cancerous cell proliferation, inhibiting the spread of cancer to other sites and improving the probability of life expectancy Minimal side effects, improving patient quality of life and providing a significant market advantage Technology This technology is a specially designed therapeutic that treats and prevents cell proliferation diseases such as cancer. Small drug-like molecules are used to bind the dichloroacetate (DCA) binding pocket of pyruvate dehydrogenase kinase isoform 2 (PDK2) and inhibit cancer cell proliferation. A patient suffering from or susceptible to a PDK2 mediated disorder or disease is administered a therapeutically effective amount of a compound that activates PDK2 activity, thereby receiving treatment.
Owner: 
University of Florida
Dislike
0
Description

Uses Small Drug-Like Molecules to Prevent Cancer Cell Proliferation

This breakthrough approach to treating cancer is efficacious and has limited side effects. Cancer is a leading cause of death in the United States, accounting for one in four deaths annually, according to the American Cancer Society. An estimated 595,600 Americans will die of cancer-related causes in 2016, and predictions for the future continue to rise. Existing treatments often suffer from a lack of efficacy or lead to debilitating side effects for the patient. Researchers at the University of Florida have developed a distinct therapy to specifically target cancerous cell proliferation and halt the growth of tumors and the spread of cancer. This breakthrough treatment also has minimal side effects, making it a desirable treatment for both the patient and health practitioner.

Application

A therapeutic cancer treatment that inhibits the proliferation of cancer

Advantages

  • Capable of preventing and treating cancer and other cell proliferation diseases, offering a therapy that is effective at a lower concentrations
  • Decreases cancerous cell proliferation, inhibiting the spread of cancer to other sites and improving the probability of life expectancy
  • Minimal side effects, improving patient quality of life and providing a significant market advantage

Technology

This technology is a specially designed therapeutic that treats and prevents cell proliferation diseases such as cancer. Small drug-like molecules are used to bind the dichloroacetate (DCA) binding pocket of pyruvate dehydrogenase kinase isoform 2 (PDK2) and inhibit cancer cell proliferation. A patient suffering from or susceptible to a PDK2 mediated disorder or disease is administered a therapeutically effective amount of a compound that activates PDK2 activity, thereby receiving treatment.

Date:08-20-2012
Applicants:University of Florida
Access to additional documentation:Please inquire
Case Ref:12854
Application number:US8492344
Inventors:David A. Ostrov, Peter W. Stacpoole, Arun Srivastava,
Support from inventors:Please inquire
Industry:Healthcare
Meta information:
Meta title:
Publication number:
Priority number:
Please fill out the form and press 'send'
Contact Seller
Please provide your contact information below.

Use this form to contact the IP-owner - you should provide an email of your choice for contact. Indicate your interest/reason for the contact.
Disclaimer: Licentix do not guarantee that message sent using this form will be read by the recipient. Please contact us if you are not recieving any response.